Secondhand Tobacco Smoke and Cardiovascular Disease
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age40+
SponsorUniversity of California, San Francisco
About this trial
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Eligibility criteria
Qualifiers
Must be able to understand and provide informed consent.
Adults >= 40 years of age.
Must have a history of occupational exposure to secondhand tobacco smoke for at least 5 years such as flight attendants who worked for airlines before the smoking ban on aircrafts went into effect or casino workers who worked at casinos with no smoke-free policies.
Lifetime smoking history equivalent to < 1 pack-year and
Disqualifiers
Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
Subject is pregnant, breast-feeding, or plans to become pregnant.
Current therapy with angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).
Known intolerance to ACE inhibitor or ARB.
Trial design
Treatments tested in this trial
- Losartan
- Placebo
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, San Francisco
Lead sponsor
Flight Attendant Medical Research Institute
Collaborator
Source ClinicalTrials.gov